Nasal Spray Delivers Vesicles to Brain, Shows Alzheimer’s Benefits

Scientists have developed an experimental nasal spray using extracellular vesicles—naturally occurring nanoscale particles secreted by cells and capable of carrying bioactive molecules that influence cellular and tissue function. These vesicles were isolated from the amniotic membrane and administered intranasally to animal models of Alzheimer’s disease.

How the vesicles reached and acted in the brain

The researchers confirmed that the vesicles successfully reached the hippocampus—a key brain region central to memory formation and severely affected in Alzheimer’s disease. Once there, they entered both neurons and microglial cells, the latter playing a critical role in monitoring the brain’s microenvironment and responding to inflammatory signals.

Effects on neuroinflammation and neural structure

Experimental results demonstrated that the vesicles helped restructure the brain’s inflammatory environment and modulated microglial activity. This shift created more favorable conditions for neuronal survival and function. The vesicles also influenced synapses—the junctions enabling communication between neurons—by increasing levels of proteins associated with synaptic plasticity and improving markers of synaptic transmission.

Cognitive outcomes in animal models

These biological changes translated into measurable improvements in cognitive performance. Animal models showed enhanced memory and cognitive abilities, including recognition memory, spatial memory, and working memory. The treatment also appeared to help prevent memory deficits and mitigate cognitive decline after its onset.

Validation in human-derived neurons

To reinforce these findings, researchers tested the vesicles on human neurons generated from induced pluripotent stem cells. These neurons were derived from skin samples taken from both Alzheimer’s patients and healthy individuals. The experiments again revealed protective effects of the vesicles on human neuronal cells.

Novel therapeutic strategy beyond amyloid and tau

The study’s significance lies in its focus on the cellular microenvironment surrounding neurons—not solely on Alzheimer’s-associated proteins such as beta-amyloid and tau. Findings suggest that adjusting microglial behavior and molecular signaling pathways linked to inflammation may support synaptic integrity and preserve brain function.

Preclinical status and future implications

The researchers emphasized that the results are preliminary and preclinical. The treatment has not yet been tested in humans and is not currently available as an Alzheimer’s therapy. Nevertheless, the work opens a promising research pathway: exploring how natural anti-inflammatory and tissue-protective mechanisms employed by the placenta—via extracellular vesicles—could be harnessed to develop new treatments for neurodegenerative diseases.